FDA-cleared profile

EFAI Chestsuite XR Malpositioned ETT Assessment System (ETT-XR-100)

Ever Fortune.AI, Co., Ltd. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.

Clinical role
Notification-only case-level triage for a malpositioned single-lumen ETT; it is not a standalone diagnostic or rule-out system.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: The software does not assess esophageal intubation, may issue a false alert for a properly positioned double-lumen ETT, does not account for patient position, and does not replace clinician review.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Adult AP chest X-ray in DICOM with a single-lumen endotracheal tube.
  • Who uses it?Intended users: Radiologists and other qualified healthcare professionals reviewing adult AP chest radiographs in acute-care settings.
  • What does the software produce?Output: Case-level text/JSON result sent to PACS or a workstation for worklist triage; no image markup is added.
  • What is its most important limitation?Key limitation: The software does not assess esophageal intubation, may issue a false alert for a properly positioned double-lumen ETT, does not account for patient position, and does not replace clinician review.

Clinical takeaway. Clinical role: Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.

Evidence takeaway. Evidence from the reviewed source record: The FDA-described retrospective, blinded, multisite study included 940 AP chest radiographs from 940 patients: 259 positive and 681 negative by a majority reference of three U.S. board-certified radiologists. Sensitivity was 0.890, specificity 0.935 and reported processing time 2.49 minutes.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Passive triage of adult AP chest radiographs for an endotracheal-tube tip more than 7 cm above the carina, less than 3 cm above the carina, below the carina in the right or left mainstem, or other listed malposition states.
  • Exact FDA submission
  • Checked 2026-09-07
Workflow role
Notification-only case-level triage for a malpositioned single-lumen ETT; it is not a standalone diagnostic or rule-out system.
  • Exact FDA submission
  • Checked 2026-09-07
Required input
Adult AP chest X-ray in DICOM with a single-lumen endotracheal tube.
  • Exact FDA submission
  • Checked 2026-09-07
Output and clinician action
Case-level text/JSON result sent to PACS or a workstation for worklist triage; no image markup is added.
  • Exact FDA submission
  • Checked 2026-09-07
Care setting
Hospital and acute-care imaging workflows where adult AP chest radiographs are used to assess endotracheal-tube position.
  • Exact FDA submission
  • Checked 2026-09-07
Intended users
Radiologists and other qualified healthcare professionals reviewing adult AP chest radiographs in acute-care settings.
  • Exact FDA submission
  • Checked 2026-09-07
Limitations
The software does not assess esophageal intubation, may issue a false alert for a properly positioned double-lumen ETT, does not account for patient position, and does not replace clinician review.
  • Exact FDA submission
  • Checked 2026-09-07
Evidence summary
The FDA-described retrospective, blinded, multisite study included 940 AP chest radiographs from 940 patients: 259 positive and 681 negative by a majority reference of three U.S. board-certified radiologists. Sensitivity was 0.890, specificity 0.935 and reported processing time 2.49 minutes.
  • Exact FDA submission
  • Checked 2026-09-07

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The FDA-described retrospective, blinded, multisite study included 940 AP chest radiographs from 940 patients: 259 positive and 681 negative by a majority reference of three U.S. board-certified radiologists. Sensitivity was 0.890, specificity 0.935 and reported processing time 2.49 minutes.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Reported sensitivity
0.89
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Exact-submission AP-only retrospective study.

Reported specificity
0.935
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07

Exact-submission AP-only retrospective study.

ETT malposition sensitivity

0.89 proportion

  • EndpointSensitivity
  • Population940 adult AP chest radiographs: 259 positive and 681 negative by the FDA reference standard
  • Tested versionETT-XR-100 configuration submitted in K242821

ETT malposition specificity

0.935 proportion

  • EndpointSpecificity
  • Population940 adult AP chest radiographs: 259 positive and 681 negative by the FDA reference standard
  • Tested versionETT-XR-100 configuration submitted in K242821

ETT malposition processing time

2.49 minutes

  • EndpointReported processing time
  • Population940 adult AP chest radiographs in the FDA-described study
  • Tested versionETT-XR-100 configuration submitted in K242821

ETT-XR-100 malposition assessment study

  • DesignRetrospective, blinded, multisite study with majority reference from three U.S. board-certified radiologists
  • Population940 adult AP chest radiographs from 940 patients, including 259 positive and 681 negative cases
  • Scopeexact submission
  • Tested versionETT-XR-100 configuration submitted in K242821
  • Samplen=940
  • IndependenceSponsor or vendor study

K242821

FDA reports sensitivity 0.890, specificity 0.935 and processing time 2.49 minutes. Subgroups included gender, age, race, manufacturers and confounders.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-07

The downloaded exact-ID recall packet contained zero records; this limited result does not establish absence of recall or safety information.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult AP chest X-ray in DICOM with a single-lumen endotracheal tube.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-07 · FDA 510(k) K242821: EFAI Chestsuite XR Malpositioned ETT Assessment System

  2. Routing

    Source context, not route validation: The result is transmitted as a case-level text/JSON notification to PACS or a workstation for passive worklist triage.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-07 · FDA 510(k) K242821: EFAI Chestsuite XR Malpositioned ETT Assessment System

  3. AI processing

    Source context, not route validation: Software connected to DICOM imaging workflow; the public FDA summary does not establish the customer's hosting, routing or support topology.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-07 · FDA 510(k) K242821: EFAI Chestsuite XR Malpositioned ETT Assessment System

  4. Returned objects

    Source context, not route validation: Case-level text/JSON result sent to PACS or a workstation for worklist triage; no image markup is added.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-07 · FDA 510(k) K242821: EFAI Chestsuite XR Malpositioned ETT Assessment System

  5. Viewer/worklist/report

    Unresolved route: Case-level text/JSON result sent to PACS or a workstation for worklist triage; no image markup is added.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-07 · FDA 510(k) K242821: EFAI Chestsuite XR Malpositioned ETT Assessment System

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Software connected to DICOM imaging workflow; the public FDA summary does not establish the customer's hosting, routing or support topology.
  • Exact FDA submission
  • Checked 2026-09-07
Integration
The result is transmitted as a case-level text/JSON notification to PACS or a workstation for passive worklist triage.
  • Exact FDA submission
  • Checked 2026-09-07
Security
Ever Fortune.AI's investor information-security policy page states an implemented information security management system covering confidentiality, integrity, and availability, with security training and measurement targets; the page states the company has completed ISO 27001 certification and holds ISO/IEC 27701 PII-processor certification after independent third-party audit. The company's certification-milestones page lists ISO/IEC 27001:2022, ISO 22301:2019, ISO/IEC 27018:2019, and ISO/IEC 27017:2015.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; certificates were not read. Applicant name variants (including uppercase and punctuation variants of Ever Fortune.AI Co., Ltd.) are bridged via the vendor's EFAI product naming and the owning domain everfortuneai.com.tw. Exact-release scope is not established.

Case-level PACS/workstation triage

The cleared system returns text/JSON case results for worklist triage and does not add image markup.

exact submission · checked 2026-09-07

ChestSuite worklist workflow

The current EverFortune.AI ChestSuite page describes four chest findings in a single pass, AI-flagged studies surfaced to the top of the worklist and pre-annotated findings before radiologist review.

product family · checked 2026-09-07

This family description does not establish the exact K242821 hosting, DICOM connector or service contract.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K242821
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-07
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2025-02-20
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-07Last searched
25Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored candidate metadata was screened; no PubMed or trial IDs were returned for this submission. This is not a full-paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-07 - Exact FDA submission

    No public price or quote for ETT-XR-100 was reviewed.

  • Pricing model: Not verified - checked 2026-09-07 - Exact FDA submission

    License, per-study, subscription and implementation terms were not established.

  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Ever Fortune.AI EFAI reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA 510(k) K242821: EFAI Chestsuite XR Malpositioned ETT Assessment System

    U.S. Food and Drug Administration - Accessed 2026-09-07

    Scope: identity, purpose, clinicalUse, modality, anatomy, workflowRole, intendedUsers, careSetting, input, output, limitations, integration, deployment, reportedSensitivity, reportedSpecificity, evidenceMetrics, evidenceStudies

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. EFAI Chestsuite XR Malpositioned ETT Assessment System (ETT-XR-100) model card (K242821)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. ChestSuite | EverFortune.AI

    EverFortune.ai - Accessed 2026-09-07

    Scope: productFamilyContext, clinicalUse, implementationCapabilities

  8. Ever Fortune.AI: Information Security Policy (ISO 27001 / ISO 27701)

    Ever Fortune.AI - Accessed 2026-10-27

    Scope: security

Research history

  1. K242821 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243808

Rayvolve PTX-PE

AZmed

Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-03-21
FDA-cleared K232410

SmartChest

Milvue

Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.

Modality
X-ray/Radiography
Anatomy
Chest/lung
Decision
2024-05-10
FDA-cleared K231871

Radify Triage

Envisionit DeepAI Ltd

Authorized purpose: Passively triage adult frontal chest X-rays for suspected pleural effusion and/or pneumothorax by providing case-level PACS worklist output; not a standalone clinical-decision tool or a rule-out result.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2024-01-17

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history